Ebola Outbreak in East Africa: Spreading Virus and
Kenya Quarantine Dispute
East Africa is currently facing a rapidly spreading Ebola epidemic caused by the rare and deadly Bundibugyo virus. The Africa Centres for Disease Control and Prevention first declared the outbreak on May 15 in the conflict-ridden eastern Democratic Republic of the Congo (DRC), with the World Health Organization (WHO) declaring a public health emergency just two days later. The virus has since crossed borders into Uganda, where 15 cases have been confirmed, including in the capital Kampala. In the DRC, 321 confirmed cases, 116 suspected cases, and 48 deaths have been recorded as of June 2.
The ongoing armed conflict in the DRC's Ituri province is severely hampering containment efforts. According to the Japan Times, a burial team was recently attacked in the South Kivu town of Katana, forcing workers to abandon the coffin and allowing community members to handle the body, an incident that could spark new chains of transmission. Furthermore, 11 patients fled isolation facilities in the Ituri epicenter, and Rimba became the 17th affected health zone in the province. Amidst the regional spread, al Jazeera and other sources report rising tensions in Kenya, where protests have erupted over an Ebola quarantine center for US citizens, and the High Court has ordered the government to release details about the facility.
There is currently no approved vaccine for the Bundibugyo strain, which has a fatality rate of 30 to 50 percent. Trish Newport of Doctors Without Borders (MSF) noted that because this is only the third outbreak of the Bundibugyo virus, pharmaceutical companies do not prioritize its research and development. She also pointed out that sweeping US foreign aid cuts under the Trump administration have forced many health organizations to withdraw from Ituri, severely impacting the response. To accelerate vaccine availability, the Coalition for Epidemic Preparedness Innovations (CEPI) is funding three candidates: the International AIDS Vaccine Initiative (IAVI) received $3.2 million, Moderna received $50 million for mRNA trials, and the University of Oxford received $8.6 million to develop a vaccine using a modified chimpanzee cold virus. While WHO experts have recommended the experimental antibody treatment MBP134 for the outbreak, Ebola expert Joanne Liu stated that general treatment remains limited to supportive care, similar to treating the flu. Experts warn that the outlook remains bleak, compounded by deep community mistrust and disinformation in the DRC, which recently led to violent protests where youths torched an Ebola treatment center in Rwampara.